Osteoprotegerin - Metabolism
Research News and Information

Sunday, November 22, 2009

Cocultures of osteoblasts and osteoclasts are influenced by local application of zoledronic acid incorporated in a poly(D,L-lactide) implant coating.

29 Sep 2009 The antiresorptive activity of bisphosphonates such as zoledronic acid (ZOL) has been shown in vitro to be because of their effect on osteoclasts and osteoblasts. However, whether the effect of ZOL on monocultures might be reproducible on cocultures ... Read more...

Osteoblast and osteoclast differentiation in an in vitro three-dimensional model of bone.

30 Aug 2009 There is increasing interest in developing new in vitro tissue models using typical tissue engineering approaches. This study was designed to (1) develop a novel three-dimensional (3D) in vitro model of bone by seeding murine primary osteoblasts and ... Read more...

NPY revealed as a critical modulator of osteoblast function in vitro: new insights into the role of Y1 and Y2 receptors.

30 Jul 2009 Neuropeptide Y (NPY) has recently emerged as a potential regulator of bone homeostasis. However, the relevance of NPY's role in osteoblast activity and the biological functions involving NPY receptors in bone homeostasis remain to be clarified. Here ... Read more...

Latest indexed articles for 'Osteoprotegerin - Metabolism'

These are the very latest articles for this heading:

• Cocultures of osteoblasts and osteoclasts are influenced by local application of zoledronic acid incorporated in a poly(D,L-lactide) implant coating. 29 Sep 2009
• Osteoblast and osteoclast differentiation in an in vitro three-dimensional model of bone. 30 Aug 2009
• NPY revealed as a critical modulator of osteoblast function in vitro: new insights into the role of Y1 and Y2 receptors. 30 Jul 2009
• Interaction of human recombinant tumor necrosis factor-related apoptosis-inducing ligand and osteoprotegerin could contribute to enhancement of the erosive processes induced by human synovial cells. 30 Jul 2009
• Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas. 30 Jul 2009
• Expression of eight genes of nuclear factor-kappa B pathway in multiple myeloma using bone marrow aspirates obtained at diagnosis. 30 Jul 2009
• Regulation of dendritic cell survival and cytokine production by osteoprotegerin. 27 Jul 2009
• ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. 14 Jul 2009
• Effect of whey protein on the proliferation and differentiation of osteoblasts. 29 Jun 2009
• Functional alpha1- and beta2-adrenergic receptors in human osteoblasts. 29 Jun 2009
• Non-association between polymorphisms of the frizzled receptor genes and bone mineral density in postmenopausal Korean women. 10 Jun 2009
• A theoretical model for simulating effect of parathyroid hormone on bone metabolism at cellular level. 30 May 2009
• Alumina ceramic particles, in comparison with titanium particles, hardly affect the expression of RANK-, TNF-alpha-, and OPG-mRNA in the THP-1 human monocytic cell line. 30 May 2009
• [The participation of RANK, RANKL and OPG in tumor osteolysis] 13 May 2009
• RANKL links arterial calcification with osteolysis. 6 May 2009
• Differential expression of determinants of glucocorticoid sensitivity in androgen-dependent and androgen-independent human prostate cancer cell lines. May 2009
• Mecp2 deficiency decreases bone formation and reduces bone volume in a rodent model of Rett syndrome. May 2009
• Mathematical modeling of spatio-temporal dynamics of a single bone multicellular unit. 29 Apr 2009
• Osteoclastogenesis in children with 21-hydroxylase deficiency on long-term glucocorticoid therapy: the role of receptor activator of nuclear factor-kappaB ligand/osteoprotegerin imbalance. 26 Apr 2009
• Mechanisms regulating increased production of osteoprotegerin by osteoblasts cultured on microstructured titanium surfaces. 21 Apr 2009

See a longer list of these articles.

Technical information about 'Osteoprotegerin'

Definition: A secreted member of the TNF receptor superfamily that negatively regulates osteoclastogenesis. It is a soluble decoy receptor of RANK LIGAND that inhibits both CELL DIFFERENTIATION and function of OSTEOCLASTS by inhibiting the interaction between RANK LIGAND and RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B.

Registry Number: 0

Descriptor UI: D053244

Alternative terms: Osteoprotegerin; Osteoclastogenesis Inhibitory Factor; Receptors, Tumor Necrosis Factor, Member 11b; Follicular Dendritic Cell-Derived Receptor-1; Follicular Dendritic Cell Derived Receptor 1; Tumor Necrosis Factor Receptor Superfamily, Member 11b; FDCR-1 Protein; FDCR 1 Protein; OCIF Protein; Tumor Necrosis Factor Receptor 11b;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; drug effects; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; ultrastructure; urine; chemistry; contraindications; agonists;

Tree Number: D12.776.543.750.705.852.760.949.249;

History Note: 2007(1997)